Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tolterodine for children with myelomeningocele and detrusor hyperreflexia:First results
Autore:
Goessl, C; Sauter, T; Michael, T; Wettig, I; Weikert, S; Miller, K;
Indirizzi:
Free Univ Berlin, Klinikum Benjamin Franklin, Urol Klin & Poliklin, D-12200 Berlin, Germany Free Univ Berlin Berlin Germany D-12200 oliklin, D-12200 Berlin, Germany
Titolo Testata:
AKTUELLE UROLOGIE
fascicolo: 5, volume: 30, anno: 1999,
pagine: 317 - 320
SICI:
0001-7868(199909)30:5<317:TFCWMA>2.0.ZU;2-P
Fonte:
ISI
Lingua:
GER
Soggetto:
INTRAVESICAL OXYBUTYNIN CHLORIDE; URINARY-TRACT DETERIORATION; NEUROGENIC BLADDER; INTERMITTENT CATHETERIZATION; ANTIMUSCARINIC AGENT; OVERACTIVE BLADDER; FOLLOW-UP; MYELODYSPLASIA; INCONTINENCE; INFANTS;
Keywords:
tolterodine; meningomyelocele; children; detrusor hyperreflexia; urodynamic;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Goessl, C Free Univ Berlin, Klinikum Benjamin Franklin, Urol Klin & Poliklin, Hindenburgdamm 30, D-12200 Berlin, Germany Free Univ Berlin Hindenburgdamm 30 Berlin Germany D-12200 rmany
Citazione:
C. Goessl et al., "Tolterodine for children with myelomeningocele and detrusor hyperreflexia:First results", AKT UROL, 30(5), 1999, pp. 317-320

Abstract

Purpose: Tolterodine is a novel anticholinergic drug with a better efficacy/tolerability profile than oxybutynin chloride in adult patients. Because data on tolterodine in pediatric patients are lacking, urodynamic effects and adverse side effects of tolterodine were investigated in children with myelomeningocele and detrusor hyperreflexia. Patients and Methods: 13 children (6 male and 7 female; 3 months to 10.7 years, mean age 5.2 years) with myelomeningocele and detrusor hyperreflexia were enrolled in this study. 7 patients received tolterodine as the initialtherapy (group 1), whereas 6 patients had previously received oxybutynin chloride (0.2-0.3 mg/kg p.o.) medication (group 2). Tolterodine tartrate wasgiven in a dose of 0.1 mg/kg orally BID with concomitant intermittent catheterization. During ongoing tolterodine medication all patients underwent urodynamic reevaluation within 3 months. Results: In group 1, an increase of maximum bladder capacity from 97.4 +/-69.1 ml to 146.0 +/- 78.9 ml (+50%; p < 0.05) and an increase of detrusor compliance from 9.1 +/- 10.6 ml/cm H2O to 13.9 +/- 9.6 ml/cm H2O (+54%; p <0.05) could be demonstrated as well as a mean decrease of maximum detrusorpressures from 70.1 +/- 31.5 cm H2O to 41.1 +/- 14.4 cm H2O (-41 %; p < 0.05). in group 2, no urodynamic difference between tolterodine and oxybutynin chloride was found. Adverse reactions to tolterodine were not noted in either group. Conclusion: From these preliminary data we conclude that tolterodine may be as effective as oxybutynin chloride, but is better tolerated in pediatricpatients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 19:23:23